Korsmeyer–Peppas’ model [Design Issues]
Hi Helmut,
just want to add regarding
with a recent paper1
Looks like it follows Korsmeyer–Peppas’ model
Release = (CumReleased)/(FinallyReleased) = k*tn
![[image]](img/uploaded/image205.jpg)
I know that's endless in vitro attempt but it confirms your suggestion.
To obtain an indirect estimate of plasma concentrations of free doxorubicin after administration of Liposomal Doxorubicin, the reported ratio between doxorubicinol, the major doxorubicin metabolite, and doxorubicin concentration in plasma after administration of standard doxorubicin can be used.
Based on the measurement of doxorubicinol, which usually represents 40–50% of the free doxorubicin concentrations, plasma concentrations of free doxorubicin after liposomal administration remain very low, approximately 0.25–1.25% of the total measured drug.2
just want to add regarding
❝ I don’t expect a lag-time. I would rather say that doxo follows Le Chatelier’s principleand is simply driven out from the liposomes due to the concentration gradient (Cliposomes > Cblood).
with a recent paper1
Looks like it follows Korsmeyer–Peppas’ model
Release = (CumReleased)/(FinallyReleased) = k*tn
![[image]](img/uploaded/image205.jpg)
I know that's endless in vitro attempt but it confirms your suggestion.
To obtain an indirect estimate of plasma concentrations of free doxorubicin after administration of Liposomal Doxorubicin, the reported ratio between doxorubicinol, the major doxorubicin metabolite, and doxorubicin concentration in plasma after administration of standard doxorubicin can be used.
Based on the measurement of doxorubicinol, which usually represents 40–50% of the free doxorubicin concentrations, plasma concentrations of free doxorubicin after liposomal administration remain very low, approximately 0.25–1.25% of the total measured drug.2
- Fateme Haghiralsadat et al. (2017) A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery, Artificial Cells, Nanomedicine, and Biotechnology, 46:1, 169–177, doi:10.1080/21691401.2017.1304403.
- Gabizon, A., Shmeeda, H. & Barenholz, Y. Clin Pharmacokinet (2003) 42: 419–436. doi:10.2165/00003088-200342050-00002.
—
Kind regards,
Mittyri
Kind regards,
Mittyri
Complete thread:
- Counterintuitive? nobody 2018-04-03 11:16 [Design Issues]
- Counterintuitive? bebac_fan 2018-04-03 18:20
- Counterintuitive? nobody 2018-04-03 23:25
- Counterintuitive? bebac_fan 2018-04-04 00:43
- Counterintuitive? nobody 2018-04-04 11:03
- Counterintuitive? bebac_fan 2018-04-04 00:43
- What is clinically relevant? Helmut 2018-04-04 16:49
- What is clinically relevant? nobody 2018-04-05 10:04
- What is clinically relevant? bebac_fan 2018-04-05 14:19
- What is clinically relevant? nobody 2018-04-06 09:22
- What is clinically relevant? Helmut 2018-04-06 16:10
- What is clinically relevant? bebac_fan 2018-04-06 20:53
- What is clinically relevant? Helmut 2018-04-06 22:05
- Korsmeyer–Peppas’ modelmittyri 2018-04-06 23:36
- What is clinically relevant? Helmut 2018-04-06 22:05
- What is clinically relevant? bebac_fan 2018-04-06 20:53
- Counterintuitive? nobody 2018-04-03 23:25
- Counterintuitive? bebac_fan 2018-04-03 18:20